5.2% Above Target

Wall Street's consensus price target for CRI is $40.33, -5.2% from its current price of $42.54. The below-market target from 24 analysts suggests limited near-term appreciation.

CRI has a consensus rating of "Buy" based on 24 Wall Street analysts. The rating breakdown is mixed, with 8 Hold ratings making up the largest segment. The consensus 12-month price target of $40.33 implies -5.2% downside from current levels.

With a forward P/E of 12.8485x, CRI trades at a relatively low valuation. The consensus target of $40.33 implies -5.2% move, suggesting the market may be pricing in risks.

The most bullish Wall Street analyst has a price target of $42 for CRI, while the most conservative target is $38. The consensus of $40.33 represents the median expectation. Our quantitative valuation model projects a bull case target of $90 based on optimistic growth and margin assumptions. These targets typically reflect 12-month expectations.

CRI is well covered by analysts, with 24 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 12 have Buy ratings, 8 recommend Hold, and 4 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.

The 12-month CRI stock forecast based on 24 Wall Street analysts shows a consensus price target of $40.33, with estimates ranging from $38 (bear case) to $42 (bull case). The median consensus rating is "Buy". Our proprietary valuation model produces a base case fair value of $68, with bear/bull scenarios of $43/$90.

Our quantitative valuation model calculates CRI's fair value at $68 (base case), with a bear case of $43 and bull case of $90. The model uses discounted cash flow analysis, historical growth rates, and margin mean-reversion to project FY+2 earnings, then applies an appropriate P/E multiple. The model confidence score is 51/100.

CRI trades at a forward P/E ratio of 12.8x based on next-twelve-months earnings estimates compared to a trailing P/E of 16.4x. The lower forward P/E indicates analysts expect earnings growth. A forward P/E is useful for comparing valuations when earnings are expected to change significantly.

Analysts are cautious on CRI, with 4 Sell ratings and a price target of $40.33 (-5.2% from current price). The "Buy" consensus suggests careful evaluation before buying. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.

CRI analyst price targets range from $38 to $42, a 10% tight range reflecting strong analyst consensus. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $40.33 consensus represents the middle ground. Our model's $43-$90 range provides an independent fundamental perspective.